Insmed, Inc. $INSM is Eagle Health Investments LP’s 4th Largest Position

Eagle Health Investments LP trimmed its stake in Insmed, Inc. (NASDAQ:INSM) by 22.3% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 210,900 shares of the biopharmaceutical company’s stock after selling 60,700 shares during the period. Insmed makes up about 8.1% of Eagle Health Investments LP’s investment portfolio, making the stock its 4th biggest position. Eagle Health Investments LP’s holdings in Insmed were worth $36,705,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in INSM. CIBC Private Wealth Group LLC boosted its position in Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 53 shares during the period. CoreCap Advisors LLC purchased a new stake in Insmed in the 4th quarter valued at about $27,000. SBI Securities Co. Ltd. boosted its position in Insmed by 404.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 166 shares during the period. GraniteShares Advisors LLC purchased a new stake in Insmed in the 4th quarter valued at about $30,000. Finally, Whittier Trust Co. of Nevada Inc. boosted its position in Insmed by 169.7% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 240 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 151 shares during the period.

Insmed Trading Up 0.5%

NASDAQ INSM opened at $107.91 on Thursday. The company has a quick ratio of 4.10, a current ratio of 4.47 and a debt-to-equity ratio of 0.80. The firm has a market cap of $23.39 billion, a PE ratio of -18.77 and a beta of 0.89. The company has a 50 day moving average price of $139.24 and a 200 day moving average price of $161.82. Insmed, Inc. has a 52 week low of $64.85 and a 52 week high of $212.75.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.14. The firm had revenue of $305.96 million during the quarter, compared to analyst estimates of $300.81 million. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. Insmed’s revenue was up 229.7% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.42) EPS. As a group, sell-side analysts forecast that Insmed, Inc. will post -2.52 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on INSM. Stifel Nicolaus boosted their price objective on shares of Insmed from $205.00 to $208.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Raymond James Financial initiated coverage on shares of Insmed in a research report on Friday, April 10th. They issued an “outperform” rating and a $200.00 price target for the company. HC Wainwright reaffirmed a “buy” rating on shares of Insmed in a research report on Friday, May 8th. Leerink Partners upped their price target on shares of Insmed from $210.00 to $215.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 24th. Finally, Guggenheim lowered their price target on shares of Insmed from $230.00 to $226.00 and set a “buy” rating for the company in a research report on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Insmed has a consensus rating of “Moderate Buy” and an average target price of $210.95.

Insider Buying and Selling

In related news, insider Michael Alexander Smith sold 19,638 shares of the business’s stock in a transaction that occurred on Monday, March 30th. The shares were sold at an average price of $150.98, for a total transaction of $2,964,945.24. Following the completion of the transaction, the insider owned 51,871 shares in the company, valued at $7,831,483.58. The trade was a 27.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO William Lewis sold 10,699 shares of the business’s stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $143.97, for a total transaction of $1,540,335.03. Following the transaction, the chief executive officer owned 301,185 shares of the company’s stock, valued at approximately $43,361,604.45. This trade represents a 3.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 150,494 shares of company stock worth $23,846,784 in the last 90 days. 2.10% of the stock is owned by corporate insiders.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.